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Effects of Weight Reduction, Exercise, and Diet Modification on Lipids
and Apolipoproteins A-l and B in Severely Obese Persons*
J. David Fachnie, MD^ and Craig C. Foreback, FhD^

We assessed the lipid and apolipoprotein effects of hypocaloric dieting, increased physical activity,
and dietary modification in severely overweight adults (body mass index [BMI] 43.05 kg/m-). The 34
women and four men enrolled in the ambulatory weight control program donated blood before,
during, and after hypocaloric dieting (420 kcal/day).
Mean values before dieting included cholesterol of223 mg/dL, high-density lipoprotein (HDL)
cholesterol of 43 mg/dL, and cholesterol/HDL cholesterol of 5.90. This placed our subjects at high
riskfor coronary artery disease. Other values included triglycerides of 138 mg/dL, apolipoprotein A-l
of 152 mg/dL. and apolipoprotein B/apolipoprotein A-l of 0.64. Significant reductions during
hypocaloric dieting included mean cholesterol of 171 mg/dL, triglycerides of 99 mg/dL. and
apolipoprotein A-l of 120 mg/dL. During weight maintenance (mean BMI 36.08 kg/m^). significant
reductions compared to baseline included a mean cholesterol of204 mg/dL and cholesterol/HDL
cholesterol of 4.60. Also, a significant increase occurred in HDL cholesterol (51 mg/dL). but a
nonsignificant elevation was observed in apolipoprotein A-l (180 mg/dL). In four subjects, discordant
ratios of cholesterol/HDL cholesterol or apolipoprotein B/apolipoprotein A-1 were seen. and one ratio
improved in two subjects despite relapse of obesity. Changes in both HDL composition and HDL
particle concentration may explain elevations of HDL cholesterol and apolipoprotein A-l after
dieting. Discordance between lipid and apolipoprotein ratios may occur. Improvement in lipids or
apolipoproteins may be seen despite regained weight. (Henry FordHosp MedJ 1987:35:216-20)

ata from the National Health and Nutrition Examination
Surveys (1,2) show that obese persons are more apt to have
hypertension, diabetes mellitus, or hypercholesterolemia (1).
Even children who are more obese have higher levels of the adverse lipids, low-density lipoprotein (LDL) cholesterol and triglycerides, and lower levels of the favorable lipids, high-density
lipoprotein (HDL) cholesterol (2). The association of obesity
with dyslipidemias, diabetes mellitus, and hypertension may be
responsible for an increased risk of coronary artery disease
(CAD) in obese adults (3).
An important question is to what extent will obese persons
who attain a stable, lower weight manifest reduction in these risk
factors? The effects of dietary weight reduction upon the dyslipidemia of the obese have been studied in 282 subjects of diverse degrees of adiposity, under various dietary regimes, and
using several different measures of lipoprotein metabolism
(4-15).
The stability of changes in lipoproteins is most important
from the standpoint of whether reduced CAD risk may be obtained. A smaller number of obese persons (112) had their lipids
evaluated after they attained a stable, lower weight (6-9,11-15).
Measurement of apolipoproteins (Apo) A - l and B, the major
protein components of high- and low-density lipoproteins, respectively, is fundamental to better understand the effects of
weight reduction on lipoprotein physiology. However, only one
report has included Apo A - l and B measurements in long-term
follow-up (II). This report describes our experience in measur-
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ing semm lipids and Apo A-l and B in a group of severely overweight adults who attended an ambulatory intensive weight
reduction program. The objective was to assess the effects of
acute weight loss brought on by a very low calorie diet (VLCD).
Later, the same measures were repeated when the subjects were
on a weight maintenance diet after a stable, lower weight had
been achieved.

Experimental Subjects
The original patient population consisted of predominantly
white, middle-class adults who were severely overweight (I)'
The subjects recmited included 34 women (aged 25 to 60 years,
mean 42 years) and four men (aged 32 to 50 years, mean 42
years). They agreed to follow the program and to donate blood
specimens as necessary to monitor the metabolic effects of
weight reduction. Of the women, all except three were prS'
menopausal, four were on estrogen or progesterone prepara'
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Table 1
Weight and Body Mass Index at Baseline,
Phase 2, and Phase 3*
Weigh' (kg)
Bodyffl^ssindex

(Icg/m-)
Weeks

Baseline
Phase 2
116.38 (88-191) 103.04(171-165)
43.05 (35-55)

kgj2!L

37.88 (29-56)
8.76 (2-16)
13.34

Baseline

Phase 3
94.76(74-127)
36.08 (30-51)
33.04 (12-88)
21.62

•Numbers are means with ranges in parentheses.

tions, and six were on a thiazide diuretic or beta blocker before
dieting. Of the men, two were on a thiazide diuretic before dieting. Thiazide diuretics were discontinued in all patients after
dietary treatment began.

Materials and Methods
After a detailed history, physical examination, electrocardiogram, and Minnesota Multiphasic Personality Inventory,
fasting semm was obtained and assayed for triglyceride, cholesterol, and HDL cholesterol using standard methods (16-18).
Total semm Apo A-l and B were assayed with a commercial assay by ligand combined with nephilometry (19,20). All subjects
met the criteria for need and safety of a VLCD. The VLCD is
defined as less than 800 kcal/day. All subjects signed an informed consent that outlined potential hazards and the need to
comply rigidly with our instmctions.
Dietary intervention occurred in three phases. Phase 1 was a
1,000 to 1,200 kcal/day balanced-deficit diet that lasted two to
three weeks. Phase 2 was a VLCD diet including 420 kcal/day,
70 g protein, 30 g carbohydrate, 2 g fat, and vitamin and mineral
supplementation (Optifast 70®, Sandoz Corporation, NY). The
phase 2 diet was to be continued for 16 weeks or unril goal
weight was achieved. Goal weight was defined by the subject
and physician as being a desirable and achievable weight, typically 10% to 20% over ideal body weight. Phase 3 was a 1,000
to 1,200 kcal/day balanced-deficit diet (20% protein, 50% carbohydrate, 30% fat with a P/S ratio of 1) that resulted in weight
maintenance at the termination of rapid weight loss (phase 2).
Blood specimens were obtained at baseline, at the termination of
phase 2, and during weight maintenance (phase 3). Phase 3
blood was drawn when the subject was eating 1,000 or more
kcal/day and had not lost weight for two or more weeks.
Several subjects had difficulty adhering strictly to this dietary
program. Therefore, only baseline and phase 2 data are available
for 12 subjects. Some subjects intermpted phase 2 for a variable
time and then returned. Others continued the dietary therapy,
without hiatus, for up to 36 weeks. In addition to dietary therapy, all subjects received a series of weekly lectures and support
sessions to enhance compliance, to educate about healthy and
unhealthy eating behaviors, and to encourage exercise in the
form of walking 20 to 30 minutes three or more times weekly.
Fasting semm was obtained in most subjects during phases 2 and
3. Several subjects donated blood six or more hours after their
last meal rather than in the fasting state.
Statistical analysis included calculation of mean, range, and
standard deviation. With paired t tests, comparisons were made
''etween baseline to phase 2, baseline to phase 3, and phase 2 to
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Table 2
Serum Lipids and Apolipoproteins Before, During,
and After Acute Weight Loss*
Cholesterol
Triglycerides
HDL Cholesterol
Apo A-I
ApoB
Cholesterol/
HDL Cholesterol
Apo B/Apo A-I

223(37)t
138 (29)
43 (19)
152(17)
95(17)
5.90(17)
0.64(17)

Phase 2
171 (27)t
99 (22)t
41(8)
120(10)*
61(9)
4.95 (9)
0.52 (9)

Phase 3
204 (26)t
114(18)
51 (14)t
180(12)
98 (11)
4.60 (12)t
0.56(11)

*A1I values are expressed as the mean in mg/dL.
tNumber in parentheses indicates number of subjects.
tP < 0.017 for baseline to phase 2 or baseline to phase 3.

phase 3. The Bonferroni method was used to minimize the
chance of incorrectly claiming significance, and the P-value was
set for groups of three tests at 0.017 and for two tests at 0.025.

Results
Weight data, reviewed in Table 1, showed a severely overweight sample of subjects, mean BMI 43.05 kg/m}. During
rapid weight reduction (phase 2), a mean of 13.34 kg was lost
over an 8.76-week period before phase 2 blood was drawn.
When weight maintenance was achieved (phase 3), an average of
21.62 kg had been lost over a mean of 33.04 weeks.
Baseline lipid and apolipoprotein data for all subjects are
listed in Table 2. Mean cholesterol was over the 75th percentile
for both men and women, according to Lipid Research Clinics'
normative data (21). Mean HDL cholesterol was within two standard deviations of Lipid Research Clinics' norms, but was below
ideal for both men and women according to Framingham norms
of 55 mg/dL for women and 45 mg/dL for men (22). A very high
percentage of the women (6/17 [35%]) had HDL cholesterol values below 37 mg/dL (34 mg/dL is the fifth percentile). Mean
choIesteroI/HDL cholesterol of 5.90 placed our subjects in the
same category as men with CAD (mean 5.8) or women with
CAD (mean 5.3) (23). No normative data exist for Apo A-l and
B measurements. However, the mean Apo A - l of 152 mg/dL
would not be considered depressed, and thus increasing the
CAD risk, when compared to men with CAD or female relatives
of men with CAD (24,25). Likewise, the mean Apo B of 95 mg/
dL was not elevated, and so indicative of increased CAD risk,
compared to available comparison data with female relatives of
CAD victims or putatively high-risk women with noninsulindependent diabetes mellitus (25,26).
The effect of a VLCD and a lower, stable weight on the same
measures is also summarized in Table 2. Statistical analysis
using paired t tests permitted comparison of changes in mean
response from baseline to phase 2, baseline to phase 3, and
phase 2 to phase 3. The VLCD (baseline versus phase 2) was
associated with significant reductions in cholesterol, triglycerides, and Apo A - l . Statistically insignificant reductions were
seen in Apo B, cholesterol/HDL cholesterol, and Apo B/Apo
A-l. A stable, lower weight (baseline versus phase 3) was associated with statistically significant reductions in cholesterol and
cholesterol/HDL cholesterol. A statistically significant increase
was seen in HDL cholesterol.
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Figure—Changes in cholesterol/HDL cholesterol and apolipoprotein B/apolipoprotein A-l. (a = P<0.017.)

Comparison of the cholesterol/HDL cholesterol ratio to that
of Apo B/Apo A - l revealed corresponding reductions in both
during the VLCD (phase 2) (Figure). These reductions obtained
statistical significance for cholesterol/HDL cholesterol only
during weight maintenance (phase 3).
Review of individual values of cholesterol/HDL cholesterol
and Apo B/Apo A-l before and after a stable, usually lower,
weight had been achieved (baseline versus phase 3) showed that
one or both ratios fell in most subjects (9/12 [75%]) (data not
shown). In subjects 1 and 2, substantial weight reduction was
associated with reductions in cholesterol/HDL cholesterol while
Apo B/Apo A-l increased (Table 3). In subjects 3 and 4, cholesterol/HDL cholesterol increased and Apo B/Apo A-l decreased
after weight reduction. In subject 4, reductions in Apo B/Apo
A-l occurred even though she regained weight and increased her
ratio of cholesterol/HDL cholesterol. In subject 5, a reduction in
cholesterol/HDL cholesterol was observed although all the
weight lost had been regained.

Discussion
The dyslipidemia of a group of severely overweight, middleclass Americans and the effect of both rapid weight reduction
with a VLCD and maintenance of a lower weight upon this dyslipidemia have been described. In addition to diet, the therapy

included behavior change instmction to encourage more healthy
eating behaviors and moderate exercise. Most subjects were
very sedentary before the program, but a majority reported the
equivalent of 20 minutes of walking three or more times weekly
by the period of weight maintenance. Also, most subjects were
eating a diet high in fat and calories before the program, but dietary interviews revealed efforts to restrict fat and total calories
by the time they had entered weight maintenance. Because of
the complex changes that occurred in subjects' weight, physical
activity, and the composition of the diet, our results must be interpreted as the consequence of all these changes, rather than
loss of body weight per se.
At baseline, semm lipid values suggested that the sample as a
whole may have a higher-than-average CAD risk. The mean
cholesterol of 223 mg/dL was over the 75th percentile by Lipid
Research Clinics' norms (21), and would warrant dietary treatment according to the Consensus Conference on Lowering
Blood Cholesterol (27). The mean HDL cholesterol of 43 mg/dL
placed both our women and men subjects at increased CAD risk
according to Framingham data (22), and 35% of the women had
HDL cholesterol values below 37 mg/dL (the fifth percentile is
34 mg/dL) (21). The mean cholesterol/HDL cholesterol ratio of
5.90 corresponded to studies of men and women subjects who
have CAD (23).
During rapid weight reduction, significant drops were observed in mean cholesterol (223 to 171 mg/dL or 23%) and triglycerides (138 to 99 mg/dL or 28%) without a corresponding
drop in HDL cholesterol. Significant reductions in cholesterol
and LDL cholesterol have been frequently reported immediately
after a period of hypocaloric diet-induced weight loss (2,4,8,
11,14,15). Only two studies have reported VLDL and LDL
concentrations of triglycerides and cholesterol after acute
weight reduction. Wolf and Gmndy (14) described a significant
reduction in cholesterol and VLDL cholesterol, but not LDL
cholesterol. Avogaro et al (4) described reduction in VLDL,
LDL, and total cholesterol. Therefore, without direct measures
we cannot specify whether reductions in VLDL or LDL cholesterol, or both, contributed to the dramatic reduction in cholesterol. Significant reductions in triglycerides have also been
frequently reported immediately after a period of hypocaloric
diet-induced weight loss (2,4,13-15). The reduction in triglycerides could be due to increased adipose tissue lipoprotein lipase
activity (28), perhaps associated with a reduction in VLDL triglyceride synthesis (29). Reduction in cholesterol may be related to a reduction of dietary fat and cholesterol on the VLCD
(30). Reduced cholesterol and LDL cholesterol may then be a
consequence of increased hepatic LDL receptors (31).

Table 3
Subject (Age/Sex)
1 (52/F)
2 (32/M)
3 (58/F)
4 (49/F)
5 (25/F)

Cholesterol/HDL Cholesterol
Baseline
Phase 3
3.00
3.17
6.58
4.20
2.86
2.98
4.02
4.31
7.20
4.49

Apo B/Apo A-1
Baseline
Phase 3
0.38
0.36
0.25
0.50
0.46
0.30
0.75
0.50

Body Mass Index (kg/m^)
Baseline
Phase 3
39
31
55
35
51
41
38
37
43
43

Phase 3 means after rapid weight reduction.
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During rapid weight reduction, a significant drop was also obefved in Apo A-l (152 to 120 mg/dL or 21%), but nonsignificant
jeductions occurred in Apo B (95 to 61 mg/dL or 36%) and in the
ratio of Apo A-l/Apo B (0.64 to 0.52 or 19%). The reduction in
Apo A-l - the major protein component of HDL, occurred without a corresponding reduction in HDL cholesterol. This suggests that HDL particles may have increased their carriage of
cholesterol. Two prior studies have shown an increase in both
y^po A-1 and HDL cholesterol during or immediately after hypocaloric diet-induced weight loss (4,11). By contrast, Apo B,
the major protein component of LDL, and cholesterol both fell
in our subjects. This observation is consistent with prior observations of the acute effects of hypocaloric dieting on Apo B and
cholesterol. During weight maintenance at a lower weight, cholesterol, triglyceride, and HDL cholesterol rose from their
nadirs during the weight loss phase. Cholesterol remained significantly lower than baseline (223 to 204 mg/dL or 9% lower).
Tiiglycerides were not significantly lower than baseline (139 to
114 mg/dL or 17% lower). HDL cholesterol rose significantly
over baseline (43 to 51 mg/dL or 19% higher). Reductions in
cholesterol after weight loss have frequentiy been reported, but
statistical significance, compared to baseline, has only been reported once before (8). Triglycerides also commonly fall, but
significance has been achieved in only three reports (12,14,15).
HDL cholesterol elevation, to a similar, significant degree, has
been more commonly reported (6-9,11,12,14).

counsel our patients? More data are needed about the effects of
risk factor intervention on both lipids and apolipoproteins.
Measures of lipoprotein metabolism during hypocaloric dieting may support a clinical impression that the patient is complying with the dietary regimen. However, these measures are not
stable and may not correspond to values obtained after a lower
weight has been achieved and maintained. The present data have
shown reductions in cholesterol, increases in HDL cholesterol,
and reductions in the ratio of cholesterol/HDL cholesterol after a
stable, lower weight had been achieved. These favorable
changes should argue well for our subjects' CADriskif they persist over time. Two of our subjects showed improvement in the
ratios of cholesterol/HDL cholesterol or Apo B/Apo A-l despite
their having regained most of the weight lost. If this last observation can be confirmed, a more favorable outlook in terms of
CAD risk may be expected for the obese person who retums to
weight reduction therapy even after repeated failures to keep the
weight off.

We obtained reports of increased physical activity and dietary
reductions in total and saturated fat, compared to baseline.
These factors may have acted in concert with weight reduction to
elevate HDL cholesterol in our subjects. In obese, sedentary
men, increased physical activity or weight loss has been shown
to increase HDL cholesterol (32). In hypercholesterolemic men,
reduction in total and saturated fat has been associated with increased HDL cholesterol (33). We did not observe an inverse
relationship between triglycerides and HDL cholesterol during
weight reduction. Others have shown that elevations of HDL
cholesterol with weight reduction in the obese are independent
of triglycerides (6). The elevation of both HDL cholesterol and
Apo A-l during refeeding suggests that HDL particle concentration may increase after hypocaloric dieting in the obese.
During weight maintenance at a lower weight, Apo A-l and B
rose from their nadirs to levels not significantly different from
baseline levels. Nonetheless, a more favorable apolipoprotein
profile was suggested by the increase in Apo A - l , baseline 152,
to phase 3, 180 mg/dL or 18% higher, and reduction in the ratio
of Apo B/Apo A-1, baseline 0.64, to phase 3,0.56 or 13% lower
Sorbis et al (11) described a significant elevation of Apo A-l two
to three weeks after afive-weekperiod of weight loss. We are
aware of no similar reports and conclude that available data support a modest increase in Apo A-l levels after a stable, lower
Weight has been obtained in obese persons.
Ratios of cholesterol/HDL cholesterol and the like are usefel in assessing risk for CAD (23). Two studies have shown
fet apolipoproteins may be even more useful (24,34). In four
objects, we observed discrepancies between cholesterol/HDL
(Cholesterol and Apo B/Apo A - l . For the same subjects, the cho'esterol/HDL cholesterol ratio fell when Apo B/Apo A-l rose or
^ce versa. Which ratio should we believe, and how should we
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